OBJECTIVE:Depressive symptoms are associated with poor smoking cessation outcomes, and there remains continued interest in behavioral interventions that simultaneously target smoking and depressive symptomatology. In this pilot study, we examined whether a behavioral activation treatment for smoking (BATS) can enhance cessation outcomes. METHOD: A sample of 68 adult smokers with mildly elevated depressive symptoms (M = 43.8 years of age; 48.5% were women; 72.7% were African American) seeking smoking cessation treatment were randomized to receive either BATS paired with standard treatment (ST) smoking cessation strategies including nicotine replacement therapy (n = 35) or ST alone including nicotine replacement therapy (n = 33). BATS and ST were matched for contact time and included 8 sessions of group-based treatment. Quit date was assigned to occur at Session 4 for each treatment condition. Participants completed a baseline assessment; furthermore, measures of smoking cessation outcomes (7-day verified point-prevalence abstinence), depressive symptoms (Beck Depression Inventory-II; Beck, Steer, & Brown, 1996), and enjoyment from daily activities (Environmental Reward Observation Scale; Armento & Hopko, 2007) were obtained at 1, 4, 16, and 26 weeks post assigned quit date. RESULTS: Across the follow-ups over 26 weeks, participants in BATS reported greater smoking abstinence (adjusted odds ratio = 3.59, 95% CI [1.22, 10.53], p = .02) than did those in ST. Participants in BATS also reported a greater reduction in depressive symptoms (B = -1.99, SE = 0.86, p = .02) than did those in ST. CONCLUSIONS: Results suggest BATS is a promising intervention that may promote smoking cessation and improve depressive symptoms among underserved smokers of diverse backgrounds.
RCT Entities:
OBJECTIVE:Depressive symptoms are associated with poor smoking cessation outcomes, and there remains continued interest in behavioral interventions that simultaneously target smoking and depressive symptomatology. In this pilot study, we examined whether a behavioral activation treatment for smoking (BATS) can enhance cessation outcomes. METHOD: A sample of 68 adult smokers with mildly elevated depressive symptoms (M = 43.8 years of age; 48.5% were women; 72.7% were African American) seeking smoking cessation treatment were randomized to receive either BATS paired with standard treatment (ST) smoking cessation strategies including nicotine replacement therapy (n = 35) or ST alone including nicotine replacement therapy (n = 33). BATS and ST were matched for contact time and included 8 sessions of group-based treatment. Quit date was assigned to occur at Session 4 for each treatment condition. Participants completed a baseline assessment; furthermore, measures of smoking cessation outcomes (7-day verified point-prevalence abstinence), depressive symptoms (Beck Depression Inventory-II; Beck, Steer, & Brown, 1996), and enjoyment from daily activities (Environmental Reward Observation Scale; Armento & Hopko, 2007) were obtained at 1, 4, 16, and 26 weeks post assigned quit date. RESULTS: Across the follow-ups over 26 weeks, participants in BATS reported greater smoking abstinence (adjusted odds ratio = 3.59, 95% CI [1.22, 10.53], p = .02) than did those in ST. Participants in BATS also reported a greater reduction in depressive symptoms (B = -1.99, SE = 0.86, p = .02) than did those in ST. CONCLUSIONS: Results suggest BATS is a promising intervention that may promote smoking cessation and improve depressive symptoms among underserved smokers of diverse backgrounds.
Authors: Megan E Piper; E Belle Federmen; Danielle E McCarthy; Daniel M Bolt; Stevens S Smith; Michael C Fiore; Timothy B Baker Journal: J Abnorm Psychol Date: 2008-02
Authors: John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan Journal: Nicotine Tob Res Date: 2003-02 Impact factor: 4.244
Authors: Anne N Thorndike; Susan Regan; Kathleen McKool; Richard C Pasternak; Susan Swartz; Nancy Torres-Finnerty; Nancy A Rigotti Journal: Arch Intern Med Date: 2008-01-28
Authors: M Nabil El-Khorazaty; Allan A Johnson; Michele Kiely; Ayman A E El-Mohandes; Siva Subramanian; Haziel A Laryea; Kennan B Murray; Jutta S Thornberry; Jill G Joseph Journal: BMC Public Health Date: 2007-09-06 Impact factor: 3.295
Authors: Samantha G Farris; Michael J Zvolensky; Peter J Norton; Julianna Hogan; Angela H Smith; Alexander M Talkovsky; Lorra Garey; Norman B Schmidt Journal: Behav Med Date: 2014-11-14 Impact factor: 3.104
Authors: Renee D Goodwin; Jina Pagura; Rae Spiwak; Adina R Lemeshow; Jitender Sareen Journal: Drug Alcohol Depend Date: 2011-04-22 Impact factor: 4.492
Authors: Darla E Kendzor; Lorraine R Reitzel; Carlos A Mazas; Ludmila M Cofta-Woerpel; Yumei Cao; Lingyun Ji; Tracy J Costello; Jennifer Irvin Vidrine; Michael S Businelle; Yisheng Li; Yessenia Castro; Jasjit S Ahluwalia; Paul M Cinciripini; David W Wetter Journal: Soc Sci Med Date: 2012-02-23 Impact factor: 4.634
Authors: Christine Vinci; Liang Li; Cai Wu; Cho Y Lam; Lin Guo; Virmarie Correa-Fernández; Claire A Spears; Diana S Hoover; Paul E Etcheverry; David W Wetter Journal: Health Psychol Date: 2017-07-20 Impact factor: 4.267
Authors: Yessenia Castro; Miguel Ángel Cano; Michael S Businelle; Virmarie Correa-Fernández; Whitney L Heppner; Carlos A Mazas; David W Wetter Journal: Drug Alcohol Depend Date: 2014-01-31 Impact factor: 4.492
Authors: Kristin L Schneider; Emily Panza; Barbara Handschin; Yunsheng Ma; Andrew M Busch; Molly E Waring; Bradley M Appelhans; Matthew C Whited; Jacey Keeney; Daniel Kern; Mihaela Blendea; Ira Ockene; Sherry L Pagoto Journal: Behav Ther Date: 2015-10-31